产品名称

英文名称：MK-8245

同义词

MK-8245、1030612-90-8、MK8245、MK 8245、2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid、537E7QE8LX、CHEMBL1938870、2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid、2H-Te

产品性质

CAS编号：1030612-90-8

分子式：C17H16BrFN6O4

分子量：467.26

PubChem编号：24988881

英文别名：MK-8245|1030612-90-8|MK8245|MK 8245|2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid|537E7QE8LX|CHEMBL1938870|2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid|2H-Te

规格或纯度：≥98%

英文名称：MK-8245

储存温度：避光,-20°C储存

运输条件：超低温冰袋运输

产品介绍：MK-8245是一种靶向作用于肝脏的stearoyl-CoA desaturase (SCD)（硬脂酰辅酶A去饱和酶）抑制剂，作用于人类SCD1时，IC50为1 nM，作用于大鼠和小鼠SCD1时，IC50为3 nM，具有抗糖尿病和抗高脂血症作用。Phase 2。MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy. Phase 2.

IUPAC Name：2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid

INCHI：InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)

InChi Key：UJEAABFSXKCSGI-UHFFFAOYSA-N

Canonical SMILES：C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O

Isomeric SMILES：C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O

PubChem CID：24988881

溶解性：DMSO 93 mg/mL (199.03 mM); Water <1 mg/mL (<1 mM); Ethanol <1 mg/mL (<1 mM)

敏感性：对光和热敏感

产品包装